These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 19667147)

  • 1. Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer.
    Flanagan JN; Zheng S; Chiang KC; Kittaka A; Sakaki T; Nakabayashi S; Zhao X; Spanjaard RA; Persons KS; Mathieu JS; Holick MF; Chen TC
    Anticancer Res; 2009 Sep; 29(9):3547-53. PubMed ID: 19667147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substitution at carbon 2 of 19-nor-1α,25-dihydroxyvitamin D3 with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells.
    Iglesias-Gato D; Zheng S; Flanagan JN; Jiang L; Kittaka A; Sakaki T; Yamamoto K; Itoh T; Lebrasseur NK; Norstedt G; Chen TC
    J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):269-75. PubMed ID: 21911059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
    Skowronski RJ; Peehl DM; Feldman D
    Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
    Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MART-10, a less calcemic vitamin D analog, is more potent than 1α,25-dihydroxyvitamin D3 in inhibiting the metastatic potential of MCF-7 breast cancer cells in vitro.
    Chiang KC; Chen SC; Yeh CN; Pang JH; Shen SC; Hsu JT; Liu YY; Chen LW; Kuo SF; Takano M; Kittaka A; Sun CC; Juang HH; Chen TC
    J Steroid Biochem Mol Biol; 2014 Jan; 139():54-60. PubMed ID: 24125734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.
    Chen TC; Holick MF; Lokeshwar BL; Burnstein KL; Schwartz GG
    Recent Results Cancer Res; 2003; 164():273-88. PubMed ID: 12899529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP24A1 as a potential target for cancer therapy.
    Sakaki T; Yasuda K; Kittaka A; Yamamoto K; Chen TC
    Anticancer Agents Med Chem; 2014 Jan; 14(1):97-108. PubMed ID: 23869781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MART-10, a novel vitamin D analog, inhibits head and neck squamous carcinoma cells growth through cell cycle arrest at G0/G1 with upregulation of p21 and p27 and downregulation of telomerase.
    Chiang KC; Yeh CN; Hsu JT; Chen LW; Kuo SF; Sun CC; Huang CC; Pang JH; Flanagan JN; Takano M; Kittaka A; Juang HH; Yang SW; Chen TC
    J Steroid Biochem Mol Biol; 2013 Nov; 138():427-34. PubMed ID: 24044969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human cytochrome P450-dependent differential metabolism among three 2α-substituted-1α,25-dihydroxyvitamin D(3) analogs.
    Yasuda K; Ikushiro S; Kamakura M; Takano M; Saito N; Kittaka A; Chen TC; Ohta M; Sakaki T
    J Steroid Biochem Mol Biol; 2013 Jan; 133():84-92. PubMed ID: 22982757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 19-Norvitamin D analogs for breast cancer therapy.
    Matsumoto Y; Kittaka A; Chen TC
    Can J Physiol Pharmacol; 2015 May; 93(5):333-48. PubMed ID: 25918960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent antiproliferative effects of 25-hydroxy-16-ene-23-yne-vitamin D₃ that resists the catalytic activity of both CYP27B1 and CYP24A1.
    Rhieu SY; Annalora AJ; LaPorta E; Welsh J; Itoh T; Yamamoto K; Sakaki T; Chen TC; Uskokovic MR; Reddy GS
    J Cell Biochem; 2014 Aug; 115(8):1392-402. PubMed ID: 24535953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-proliferative activity of 25-hydroxyvitamin D3 in human prostate cells.
    Munetsuna E; Kawanami R; Nishikawa M; Ikeda S; Nakabayashi S; Yasuda K; Ohta M; Kamakura M; Ikushiro S; Sakaki T
    Mol Cell Endocrinol; 2014 Feb; 382(2):960-70. PubMed ID: 24291609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells.
    Ikezoe T; Gery S; Yin D; O'Kelly J; Binderup L; Lemp N; Taguchi H; Koeffler HP
    Cancer Res; 2005 Jun; 65(11):4762-8. PubMed ID: 15930295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
    Zhao XY; Peehl DM; Navone NM; Feldman D
    Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MART-10, the vitamin D analog, is a potent drug to inhibit anaplastic thyroid cancer cell metastatic potential.
    Chiang KC; Kuo SF; Chen CH; Ng S; Lin SF; Yeh CN; Chen LW; Takano M; Chen TC; Juang HH; Kittaka A; Lin JD; Pang JH
    Cancer Lett; 2015 Dec; 369(1):76-85. PubMed ID: 26282787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
    Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
    Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D.
    Flanagan JN; Young MV; Persons KS; Wang L; Mathieu JS; Whitlatch LW; Holick MF; Chen TC
    Anticancer Res; 2006; 26(4A):2567-72. PubMed ID: 16886665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the potential therapeutic role of a new generation of vitamin D analog, MART-10, in human pancreatic cancer cells in vitro and in vivo.
    Chiang KC; Yeh CN; Hsu JT; Yeh TS; Jan YY; Wu CT; Chen HY; Jwo SC; Takano M; Kittaka A; Juang HH; Chen TC
    Cell Cycle; 2013 Apr; 12(8):1316-25. PubMed ID: 23549173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation.
    Banwell CM; Singh R; Stewart PM; Uskokovic MR; Campbell MJ
    Recent Results Cancer Res; 2003; 164():83-98. PubMed ID: 12899515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse.
    Masuda S; Byford V; Arabian A; Sakai Y; Demay MB; St-Arnaud R; Jones G
    Endocrinology; 2005 Feb; 146(2):825-34. PubMed ID: 15498883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.